
The first vaccine designed to protect infants against respiratory syncytial virus (RSV) by vaccinating their mothers during pregnancy has been backed by a panel of advisers to the U.S. Food and Drug Administration. On Thursday the independent committee of experts voted unanimously that the Pfizer-made vaccine was effective, and 10-4 that there was adequate data… read on > read on >